REGENXBIO (RGNX) Competitors

REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Do insiders & institutionals have more ownership in RGNX or ADPT?

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 13.1% of REGENXBIO shares are held by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is RGNX or ADPT more profitable?

Adaptive Biotechnologies has a net margin of -89.12% compared to REGENXBIO's net margin of -283.19%. Adaptive Biotechnologies' return on equity of -64.65% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-283.19%	-70.65%	-41.68%
Adaptive Biotechnologies	-89.12%	-64.65%	-26.45%

Which has higher valuation and earnings, RGNX or ADPT?

Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$83.33M	3.94	-$263.49M	-$4.61	-1.42
Adaptive Biotechnologies	$178.96M	6.43	-$159.49M	-$1.09	-7.10

Which has more risk and volatility, RGNX or ADPT?

REGENXBIO has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Do analysts recommend RGNX or ADPT?

REGENXBIO presently has a consensus target price of $31.88, indicating a potential upside of 386.64%. Adaptive Biotechnologies has a consensus target price of $9.40, indicating a potential upside of 21.45%. Given REGENXBIO's higher possible upside, research analysts plainly believe REGENXBIO is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Adaptive Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to RGNX or ADPT?

In the previous week, Adaptive Biotechnologies had 2 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 6 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.70 beat Adaptive Biotechnologies' score of 1.02 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in RGNX or ADPT?

REGENXBIO received 345 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 65.53% of users gave REGENXBIO an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
REGENXBIO	Outperform Votes 443 65.53%	Underperform Votes 233 34.47%
Adaptive Biotechnologies	Outperform Votes 98 57.99%	Underperform Votes 71 42.01%

Summary

Adaptive Biotechnologies beats REGENXBIO on 11 of the 17 factors compared between the two stocks.